Immunic Q4 2021 Earnings Report
Key Takeaways
Immunic, Inc. reported its year-end 2021 financial results, highlighting clinical progress across key pipeline programs, including vidofludimus calcium (IMU-838) and IMU-935. Enrollment was initiated in the Phase 3 ENSURE program for relapsing multiple sclerosis, and positive results were reported from the Phase 1 clinical trial of IMU-935.
Initiated enrollment in Phase 3 ENSURE program of Vidofludimus Calcium for the treatment of relapsing multiple sclerosis.
Final Cohort 2 data from the Phase 2 EMPhASIS Trial confirms Phase 3 dose selection.
Completed enrollment of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in moderate-to-severe Ulcerative Colitis; top-line data expected in June of 2022.
Reported positive results from the single and multiple ascending dose parts of the Phase 1 clinical trial of IMU-935.